

## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

1.-38. (Cancelled)

39. (Currently Amended) A composition for delivery of a drug, the composition comprising a condensation aerosol

a) wherein the condensation aerosol is formed by heating a thin film of a drug composition to produce a vapor, and condensing the vapor to form a condensation aerosol comprising the drug,

b) wherein the condensation aerosol comprises particles that are characterized by less than 10% drug degradation products by weight,

c) wherein the condensation aerosol has an MMAD of less than 5 microns, and

d) wherein the drug is selected from the group consisting of albuterol, epinephrine, metaproterenol, terbutaline, pseudoephedrine hydrochloride, bambuterol, bitolterol, carbuterol, clenbuterol, clorprenaline, dioxethedrine, eprozinol, etefedrine, ethylnorepinephrine, fenoterol, fenspiride, hexoprenaline, isoetharine, isoproterenol, mabuterol, methoxyphenamine, pirbuterol, procaterol, protokylol, rimiterol, salmeterol, soterenol, tretoquinol, tulobuterol, theophylline, aminophylline, acefylline, bamifylline, doxofylline, dyphylline, etamiphyllin, etofylline, proxyphylline, reproterol, theobromine-1-acetic acid, atropine, ipratropium bromide, flutropium bromide, oxitropium bromide, tiotropium bromide, budesonide, beclomethasone, ciclesonide, dexamethasone, flunisolide, fluticasone propionate, triamcinolone acetonide, prednisolone, methylprednisolone, hydrocortisone, cromolyn sodium, nedocromil sodium, montelukast, zafirlukast, pirfenidone, CPX, IBMX, cilomilast, roflumilast, pumafentrine, domitroban, israpafant, ramatroban, seratrodast, tiaramide, zileuton, ambrisentan, bosentan, enrasentan, sitaxsentan, tezosentan, iloprost, and treprostinil.

40. (Cancelled)
41. (Previously Presented) The composition of claim 39, wherein the condensation aerosol particles are characterized by less than 5% drug degradation products.
42. (Cancelled)
43. (Previously Presented) The composition of claim 41, wherein the condensation aerosol particles are characterized by less than 1% drug degradation products.
44. (Cancelled)
45. (Previously Presented) The composition of claim 39, wherein the drug composition comprises a drug that is in a free base form.
46. (Previously Presented) The composition of claim 39, wherein the drug composition comprises a drug that is in a free acid form.
47. (Previously Presented) The composition of claim 39, wherein the drug composition comprises at least two drugs.
48. (Previously Presented) The composition of claim 39, wherein the drug composition comprises a pharmaceutically acceptable excipient.
49. (Previously Presented) The composition of claim 39, wherein the condensation aerosol is devoid of excipients.
50. (Previously Presented) The composition of claim 39, wherein the condensation aerosol is devoid of propellants and organic solvents.

51. (Previously Presented) The composition of claim 39, wherein the condensation aerosol particles are characterized by increasing percentages of drug degradation products with increasing film thicknesses.
52. (Cancelled)
53. (Previously Presented) The composition of claim 39, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.
54. (Cancelled)
55. (Previously Presented) The composition of claim 39, wherein the condensation aerosol is characterized by an MMAD of 1 to 5 microns.
56. (Cancelled)
57. (Previously Presented) The composition of claim 39, wherein the condensation aerosol is characterized by an MMAD of 10 to 100 nm.
58. (Cancelled)
59. (Previously Presented) The composition of claim 55, wherein the condensation aerosol is characterized by an MMAD of 1 to 3 microns.
60. (Cancelled)
61. (Previously Presented) The composition of claim 59, wherein the condensation aerosol particles are characterized by less than 5% drug degradation products.
62. (Cancelled)

63. (Previously Presented) The composition of claim 61, wherein the condensation aerosol particles are characterized by less than 1% drug degradation products.
64. (Cancelled)
65. (Previously Presented) The composition of claim 39, wherein the thin film has a thickness between 0.05 and 20 microns.
66. (Previously Presented) The composition of claim 65, wherein the thin film has a thickness between 0.5 and 5 microns.
67. (Previously Presented) A kit for delivering a condensation aerosol, the kit comprising:
- a) a thin film of a drug composition comprising a drug, on a solid support, and
  - b) a device for providing the condensation aerosol,
- wherein the condensation aerosol is formed by heating the drug composition to produce a vapor, and condensing the vapor to form a condensation aerosol comprising the drug,
- wherein the condensation aerosol comprises particles that are characterized by less than 10% drug degradation products by weight,
- wherein the condensation aerosol has an MMAD of less than 5 microns, and
- wherein the drug is selected from the group consisting of albuterol, epinephrine, metaproterenol, terbutaline, pseudoephedrine hydrochloride, bambuterol, bitolterol, carbuterol, clenbuterol, clorprenaline, dioxethedrine, eprozinol, etefedrine, ethylnorepinephrine, fenoterol, fenspiride, hexoprenaline, isoetharine, isoproterenol, mabuterol, methoxyphenamine, pirbuterol, procaterol, protokylol, rimiterol, salmeterol, soterenol, tretoquinol, tulobuterol, theophylline, aminophylline, acefylline, bamifylline, doxofylline, dyphylline, etamiphyllin, etofylline, proxyphylline, reproterol, theobromine-1-acetic acid, atropine, ipratropium bromide, flutropium bromide, oxitropium bromide, tiotropium bromide, budesonide, beclomethasone, ciclesonide, dexamethasone, flunisolide, fluticasone propionate, triamcinolone acetonide, prednisolone, methylprednisolone, hydrocortisone, cromolyn sodium, nedocromil sodium, montelukast, zafirlukast, pirfenidone, CPX, IBMX, cilomilast, roflumilast, pumafentrine, domitroban,

israpafant, ramatroban, seratrodast, tiaramide, zileuton, ambrisentan, bosentan, enrasentan, sitaxsentan, tezosentan, iloprost, and treprostinil.

68. (Previously Presented) The kit of claim 67, wherein the thin film has a thickness between 0.05 and 20 microns.

69. (Previously Presented) The kit of claim 67, wherein the thin film has a thickness between 0.5 and 5 microns.

70. (Previously Presented) The kit of claim 67, wherein the device comprises a heating element configured to heat the thin film to produce a vapor, and an enclosure allowing the vapor to condense to form a condensation aerosol.

71. (Previously Presented) The kit of claim 67, wherein the condensation aerosol comprises more than one drug.

72. (Previously Presented) The kit of claim 67, wherein the drug composition further comprises a pharmaceutically acceptable excipient.

73. (Cancelled)

74. (Previously Presented) The kit of claim 67, wherein the condensation aerosol has an MMAD of less than 3 microns.

75. (Previously Presented) The kit of claim 67, wherein the condensation aerosol has an MMAD of 1 to 5 microns.

76. (Previously Presented) The kit of claim 67, wherein the condensation aerosol has an MMAD of 10 to 100 nm.

77. (Previously Presented) The kit of claim 75, wherein the condensation aerosol has an MMAD of 1 to 3 microns.
78. (Previously Presented) The kit of claim 67, wherein the solid support is a metal foil.
79. (Previously Presented) The kit of claim 67, wherein the condensation aerosol particles are characterized by less than 5% drug degradation products.
80. (Previously Presented) The kit of claim 79, wherein the condensation aerosol particles are characterized by less than 1% drug degradation products.
81. (Previously Presented) The composition of claim 59, wherein the drug composition comprises a drug that is in a free base form.
82. (Previously Presented) The composition of claim 59, wherein the drug composition comprises a drug that is in a free acid form.
83. (Previously Presented) The composition of claim 59, wherein the drug composition comprises at least two drugs.
84. (Previously Presented) The composition of claim 59, wherein the drug composition comprises a pharmaceutically acceptable excipient.
85. (Previously Presented) The composition of claim 59, wherein the condensation aerosol is devoid of excipients.
86. (Previously Presented) The composition of claim 59, wherein the condensation aerosol is devoid of propellants and organic solvents.

87. (Previously Presented) The composition of claim 59, wherein the condensation aerosol particles are characterized by increasing percentages of drug degradation products with increasing film thicknesses.
88. (Previously Presented) The composition of claim 59, wherein the thin film has a thickness between 0.05 and 20 microns.
89. (Previously Presented) The composition of claim 88, wherein the thin film has a thickness between 0.5 and 5 microns.
90. (Previously Presented) The composition of claim 59, wherein the condensation aerosol is formed at a rate greater than 0.01 mg/s.
91. (Previously Presented) The composition of claim 90, wherein the condensation aerosol is formed at a rate greater than 0.9 mg/s.
92. (Previously Presented) The composition of claim 91, wherein the condensation aerosol is formed at a rate greater than 2.5 mg/s.
93. (Previously Presented) The composition of claim 39, wherein the condensation aerosol is formed at a rate greater than 0.01 mg/s.
94. (Previously Presented) The composition of claim 93, wherein the condensation aerosol is formed at a rate greater than 0.9 mg/s.
95. (Previously Presented) The composition of claim 94, wherein the condensation aerosol is formed at a rate greater than 2.5 mg/s.